2019 news highlights

February

Complete acquisition of CellforCure The deal expands our manufacturing capacity for cell and gene therapies
Announce FDA approval of Egaten It is the only medicine recommended by the WHO for liver fluke, a neglected tropical disease

March

Announce FDA approval of Mayzent It treats active secondary progressive multiple sclerosis. EU approval announced in January 2020
Receive Kymriah approval in Japan It follows the launch of the CAR-T therapy in the US, the EU and other countries